Synergistic disaggregation of platelets by tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin.
Why the study?
Does the combination of tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin synergistically disaggregate platelets?
Population
Platelets (preclinical/in vitro model)
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
May enhance thrombolytic adjunct strategies; hypothesis-generating in animals and leaves open human translation.
Key Points
- To determine whether endothelial-derived platelet inhibitors—tissue-type plasminogen activator, prostaglandins, and nitric oxide analogs—act synergistically to disperse preformed platelet aggregates.
- Tested the combined effects of tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin on the dispersion of preformed platelet aggregates.
- Investigated the alteration of intracellular platelet cyclic nucleotides as the underlying biochemical mechanism.
- Tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin acted synergistically to disperse preformed platelet aggregates.
- The synergistic disaggregation was mediated in part through the cooperative modulation of platelet cyclic nucleotide levels.
Structured PICO
Does the combination of tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin synergistically disaggregate platelets?
P
Population
Platelets (preclinical/in vitro model)
I
Intervention
Combination of tissue-type plasminogen activator, prostaglandin E1, and nitroglycerin
O
Outcome
Platelet disaggregationsurrogate
The synergistic action of tPA, prostaglandin E1, and nitroglycerin on platelet disaggregation suggests a potential mechanism for endothelial protection and a strategy for improving thrombolytic therapy efficacy.
Cite This Study
Stamler et al. (1989) studied this question.